2Q Revenues: $3.5 billion (+11%)
2Q Earnings: $615 million (+15%)
YTD Revenues: $6.8 billion (+11%)
YTD Earnings: $1.2 billion (earnings were $472 million YTD10)
Comments: BioScience revenues were up 14% to $1.6 billion (up 10% excluding the impact of foreign currency), driven by demand for Gammagard Liquid, certain specialty plasma-based therapeutics, and vaccines. Medical Products sales were up 8% to $2.0 billion in the quarter, reflecting growth of anesthesia products, nutritional therapies, infusion systems and other injectable drugs.